BLFS as reported
BioLife Solutions, Inc. reported $103M of revenue over the trailing twelve months, +25% on the year before. 10 reported series are charted on this page, each one as filed.
$103M
Revenue, trailing twelve months · to Q2 2026 · +25% against the twelve months before
- Net Income
- $58M
Net Income · −1148% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $8.6M
Free Cash Flow · −114% year on year · trailing twelve months to Q2 2026
- Op Margin
- 3.2%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $103M | +25% | Q2 2026 |
| Net Income | $58M | −1148% | Q2 2026 |
| EPS | $1.17 | −1164% | Q2 2026 |
| Gross Margin | 59% | n/a | Q3 2020 · 23 quarters behind |
| Op Margin | 3.2% | n/a | Q2 2026 |
| Net Margin | 56% | n/a | Q2 2026 |
| ROE | 2.7% | n/a | Q2 2026 |
| ROA | 2.6% | n/a | Q2 2026 |
| ROIC | −3.0% | n/a | Q2 2026 |
| Free Cash Flow | $8.6M | −114% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
BioLife Solutions, Inc. (BLFS) - Revenue & ProfitRevenue & ProfitBioLife Solutions, Inc. (BLFS)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Instruments & Supplies
Ranks #2 of 27 by Smart Score